What Sent DaVita Stock Soaring On Tuesday?
Key Points
Shares of kidney dialysis treatment company DaVita understandably struggled in 2025.
Its most recent quarterly report and guidance for the year ahead, however, were both better than anticipated.
While still far from being a growth name, this stock is undervalued at its present price.
- 10 stocks we like better than DaVita ›
Last year was a forgettable one for DaVita (NYSE: DVA) shareholders, but understandably so. The stock ended up losing 25% of its value in calendar 2025 due to a combination of a declining number of dialysis patients, subpar guidance for most of the year, uncertainty as to how much insurers were willing to continue reimbursing the company, and an embarrassing ransomware attack reported in April.
It's just possible, however, that the sellers overshot their target. As of 12:16 p.m. ET Tuesday, DaVita stock is up an impressive 20.3% in response to fourth-quarter results and full-year guidance that show more promise than problems.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
Better than expected
For the three-month stretch ending in December, DaVita turned $3.62 billion in revenue into an adjusted per-share profit $3.40. That's well up from the year-earlier comparison of $2.51 per share, when the company reported revenue of just under $3.3 billion. Perhaps more important, though, both of these numbers also topped analysts' expectations.
Image source: Getty Images.
The foreseeable future looks brighter than expected too. DaVita says it's anticipating per-share profits of between $13.60 and $15.00 for the fiscal year now underway, well up from last year's adjusted comparison of only $10.78, and versus analysts' consensus of around $13.50 per share.
More to like than not
The dialysis treatment company's core challenges remain. Those are health insurers' never-ending efforts to keep their net reimbursement costs to a minimum, and an opportunity for people to achieve better kidney health without Davita's help than they've been able to in the past. This includes home-based dialysis options.
The degree to which these headwinds are going to take a sustained toll on DaVita's business, however, appears to have been overestimated. While it's still far from being a high-growth stock, priced at only about 10 times this year's very achievable expected per-share earnings of $13.50, DaVita is certainly a very attractive value proposition even after today's surge. Just be aware there could be some post-surge volatility that will need to be wrung out from here.
Should you buy stock in DaVita right now?
Before you buy stock in DaVita, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and DaVita wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $446,319!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,137,827!*
Now, it’s worth noting Stock Advisor’s total average return is 932% — a market-crushing outperformance compared to 197% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of February 3, 2026.
James Brumley has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
